Company intelligence / Profile preview

Aspira

Austin, Texas, United States

Ownership: Public · AWHL
Development stage: Other

Overview

Aspira Women's Health has commercialized Ova1 and Overa as FDA-cleared products for detecting ovarian malignancy risk in women with adnexal masses. The company launched Ova1Plus, which combines both tests through proprietary algorithms.

Therapeutic areas: OncologyWomen's Health
Modalities: Protein biomarker assaysAI-powered diagnostic tests
Industry: Protein Biomarker Diagnostics

Partnerships

Quest Diagnostics (strategic alliance for development and commercialization of Ova1)Johns Hopkins University (biomarker discovery partnerships)Bio-Reference Laboratories (distribution and co-marketing for Ova1Plus)academic collaborations with University College LondonM.D. Anderson Cancer CenterStanfordRigshospitaletand others

Beyond the preview

Go deeper on Aspira.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aspira.

Explore the full profile